Table 2.
Effects of ITE treatment on cardiac structure and function in MI rats
| Control | Sham | Control + ITE1.6 | Control + ITE8.0 | MI | MI + ITE1.6 | MI + ITE8.0 | |
|---|---|---|---|---|---|---|---|
| HR (b.p.m.) | 488.63 ± 5.08 | 492.34 ± 6.22 | 485.02 ± 6.13 | 478.64 ± 8.22 | 488.44 ± 5.86 | 487.28 ± 6.33 | 491.02 ± 6.12 |
| IVSd (mm) | 1.73 ± 0.04 | 1.70 ± 0.07 | 1.78 ± 0.08 | 1.72 ± 0.07 | 1.35 ± 0.23* | 1.33 ± 0.10* | 1.32 ± 0.24* |
| LVDd (mm) | 6.64 ± 0.84 | 6.32 ± 0.72 | 6.79 ± 0.66 | 6.49 ± 0.74 | 10.81 ± 1.07* | 9.38 ± 0.82* | 9.41 ± 0.67* |
| LVDs (mm) | 3.71 ± 0.49 | 3.24 ± 0.58 | 3.97 ± 0.42 | 3.49 ± 0.66 | 8.05 ± 0.45* | 7.34 ± 0.39* , # | 7.13 ± 0.41* , # |
| LVPWd (mm) | 1.68 ± 0.08 | 1.66 ± 0.07 | 1.67 ± 0.08 | 1.66 ± 0.06 | 1.28 ± 0.13* | 1.32 ± 0.09* | 1.33 ± 0.16* , # |
| EF (%) | 80.71 ± 0.81 | 79.51 ± 1.54 | 78.86 ± 1.36 | 77.26 ± 2.33 | 30.29 ± 2.33* | 38.24 ± 3.51* , # | 41.17 ± 2.20* , # |
| FS (%) | 44.12 ± 0.72 | 45.04 ± 0.66 | 43.24 ± 0.88 | 44.64 ± 0.73 | 12.35 ± 2.34* | 16.10 ± 1.03* , # | 17.11 ± 1.10* , # |
| E/e′ | 10.69 ± 1.85 | 11.59 ± 1.24 | 11.05 ± 2.13 | 10.74 ± 2.13 | 32.73 ± 3.73* | 25.80 ± 2.92* , # | 26.65 ± 2.43* , # |
E/e′, the ratio of mitral valve flow in early diastole and peak annulus motion velocity; EF, ejection fraction; FS, left ventricular short‐axis shortening; ITE, 2‐(1′H‐indole‐3′‐carbonyl)‐thiazole‐4‐carboxylic acid methyl ester; IVSd, ventricular septal end‐diastolic thickness; LVDd, left ventricular end‐diastolic diameter; LVDs, left ventricular end‐systolic diameter; LVPWd, left ventricular posterior wall end‐diastolic thickness; MI, myocardial infarction.
n = 8 per group. Dataare presented as mean ± SD.
*
p < 0.05 vs. sham group.
#
p < 0.05 vs. MI group.